Imaging-based biological threat characterisation for Defence, biosecurity and biopharma.
Imaging-based biological threat characterisation for Defence, biosecurity and biopharma.
Detection tells you what is present. PCR, sequencing and proteomic panels confirm an agent against a known target. They do not show whether it is active, replicating or damaging host cells. An agent with no known genetic signature may not register at all. Containment, treatment and countermeasure decisions wait on that answer.
PathogenPrime, our imaging and analysis platform, follows infection as it happens and measures it across thousands of cells. You get evidence you can act on.
DefenSight provides sovereign, auditable biological‑effects analytics for CBRN and biosecurity missions. We convert microscopy imaging into defensible, operator‑independent intelligence that shows whether a biological agent is active, replicating, and causing harm, not just present. It shortens the time from detection to assessment to action, supporting mission-level decision-making in high-consequence environments.
Sample preparation follows lab-validated methodology. The models are interpretable: every classification shows the features behind it.
We measure pathogen activity and host-cell injury in each cell. High-content imaging runs on 96- and 384-well plates. When the question needs sub-cellular detail, super-resolution reaches about 120 nm (Airyscan) and 20 nm (STORM). Every output ships with a QC summary.
Four steps from sample to report.
1. Send samples or images. Fixed or inactivated cells, tissue or organoids. Or existing image files (.czi, .nd2, .lif, TIFF).
2. Imaging. Live-cell, confocal, super-resolution, high-content or STORM, matched to the question.
3. Analysis. Per-cell segmentation and 50+ features. Documented QC gates and versioned models.
4. Report. Results, representative images, raw and processed data, and methods text. Analysis only: 5 working days. Full study: 10 to 15 working days.
“Detection tells you what is present. Our analytics tell you whether it is active and causing harm.”
Dr Sonja Frölich, Founder and Chief Scientist
DefenSight is founder-led, with an advisory board in virology, bacteriology, translational research, research commercialisation, defence innovation, and Defence law and procurement.
Copyright © 2026 | DefenSight Pty Ltd | ABN 68 692 002 010
All Rights Reserved
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.